DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+15.27%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.01B
AUM Growth
+$5.01B
(+5.5%)
Cap. Flow
-$211M
Cap. Flow
% of AUM
-4.22%
Top 10 Holdings %
Top 10 Hldgs %
37.68%
Holding
145
New
16
Increased
15
Reduced
22
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$88.1M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
$62.8M |
| 3 |
Revolution Medicines
RVMD
|
$39.4M |
| 4 |
Larimar Therapeutics
LRMR
|
$35.6M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
$26.8M |
Top Sells
| 1 |
Viatris
VTRS
|
$85.2M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$69.6M |
| 3 |
AdaptHealth
AHCO
|
$55M |
| 4 |
Neurocrine Biosciences
NBIX
|
$53.1M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$49.7M |
Sector Composition
| 1 | Healthcare | 53.67% |
| 2 | Financials | 1.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$14.7B
| $36.1M | 0.72% |
464,000
-114,800
| -20% | -$8.93M |
|
|
AMED
27
DELISTED
Amedisys
AMED
| $34.8M | 0.69% |
359,765
+160,765
| +81% | +$15.6M |
|
28
Phreesia
PHR
$1.82B
| $34.6M | 0.69% |
1,358,000
+500,885
| +58% | +$12.8M |
|
|
BLU
29
DELISTED
BELLUS Health Inc.
BLU
| $32.5M | 0.65% |
3,081,000
+608,000
| +25% | +$6.42M |
|
30
Kura Oncology
KURA
$726M
| $30.3M | 0.6% |
2,219,128
-407,872
| -16% | -$5.57M |
|
|
31
Phathom Pharmaceuticals
PHAT
$848M
| $26.8M | 0.53% |
+2,414,897
| New | +$26.8M |
|
32
IDEAYA Biosciences
IDYA
$2.24B
| $26M | 0.52% |
+1,743,628
| New | +$26M |
|
|
VERV
33
DELISTED
Verve Therapeutics
VERV
| $25.8M | 0.51% |
+750,000
| New | +$25.8M |
|
34
Molina Healthcare
MOH
$9.66B
| $24.7M | 0.49% |
75,000
-92,000
| -55% | -$30.3M |
|
|
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
| $23.3M | 0.46% |
+816,994
| New | +$23.3M |
|
36
Tarsus Pharmaceuticals
TARS
$2.42B
| $22.7M | 0.45% |
1,324,214
| – | – |
|
37
Alphatec Holdings
ATEC
$2.33B
| $22.1M | 0.44% |
2,532,792
+112,245
| +5% | +$981K |
|
38
Insmed
INSM
$30.2B
| $20.7M | 0.41% |
960,484
| – | – |
|
|
39
Day One Biopharmaceuticals
DAWN
$773M
| $20.7M | 0.41% |
1,032,000
-2,480,123
| -71% | -$49.7M |
|
40
Enhabit
EHAB
$397M
| $20.4M | 0.41% |
+1,454,279
| New | +$20.4M |
|
|
VIGL
41
DELISTED
Vigil Neuroscience
VIGL
| $18M | 0.36% |
+2,054,794
| New | +$18M |
|
|
OMIC
42
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $17.7M | 0.35% |
7,078,019
+741,689
| +12% | +$1.85M |
|
43
TG Therapeutics
TGTX
$4.97B
| $15.9M | 0.32% |
2,677,500
| – | – |
|
|
DALS
44
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.6M | 0.31% |
1,600,000
| – | – |
|
45
The Oncology Institute
TOI
$302M
| $15.6M | 0.31% |
3,360,052
-23,047
| -0.7% | -$107K |
|
46
Pacira BioSciences
PCRX
$1.22B
| $15.5M | 0.31% |
292,000
| – | – |
|
47
GeneDx Holdings
WGS
$3.65B
| $14.9M | 0.3% |
16,973,488
-1,875,000
| -10% | -$1.65M |
|
48
Rocket Pharmaceuticals
RCKT
$356M
| $13.9M | 0.28% |
+870,000
| New | +$13.9M |
|
49
AN2 Therapeutics
ANTX
$33.6M
| $12.5M | 0.25% |
716,538
| – | – |
|
50
Krystal Biotech
KRYS
$4.36B
| $12.2M | 0.24% |
+175,000
| New | +$12.2M |
|